Targeted drug delivery by gemtuzumab ozogamicin: Mechanism-Based mathematical model for treatment strategy improvement and therapy individualization

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Jager, Eva ^a   van der Velden, Vincent H J ^b   te Marvelde, Jeroen G ^b   Walter, Roland B ^c,d   Agur, Zvia ^a,e   Vainstein, Vladimir ^a  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Optimata Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; GEMTUZUMAB; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; CELL SURFACE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; INDIVIDUALIZATION; INTERNALIZATION; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PREDICTION; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TREATMENT PLANNING; VALIDATION PROCESS; METABOLISM; THEORETICAL MODEL; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, THEORETICAL;

EID: 80052540027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024265     Document Type: Article

References (23)

1. Linenberger ML, (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19: 176-182.
2. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, et al. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97: 3197-3204.
3. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442-1452.
4. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG, et al. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in MRC AML15 trial. Blood 108 Abstract 13.
5. Gleissner B, Schlenk R, Bornhauser M, Berdel WE, (2007) Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia-ongoing trials. Onkologie 30: 657-662.
6. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS, (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41: 1206-1214.
7. Lobo ED, Hansen RJ, Balthasar JP, (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668.
8. Resat H, Ewald JA, Dixon DA, Wiley HS, (2003) An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys J 85: 730-743.
9. Sato H, Sugiyama Y, Tsuji A, Horikoshi I, (1996) Importance of receptor-mediated endocytosis in peptide dekivery and targeting: kinetic aspects. Adv Drug Del Rev 19 (3): 445-467.
10. Tzafriri AR, Wu D, Edelman ER, (2004) Analysis of compartmental models of ligand-induced endocytosis. J Theor Biol 229: 127-138.
11. Wiley HS, Cunningham DD, (1981) A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands. Cell 25: 433-440.
12. Mager DE, Jusko WJ, (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28: 507-532.
13. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ, (2005) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22: 1088-1100.
14. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L, (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23: 95-103.
15. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, et al. (2004) High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18: 983-988.
16. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, et al. (2007) CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109: 4168-4170.
17. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, et al. (2004) Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18: 316-325.
18. Sergio A, Stefan S, Dominik S, Giuliana A, Liliana B, Vittorio R, et al. (2008) Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial.
19. Report of the task group on reference man (ICRP 23): anatomical, physiological and metabolic characteristics: Elsevier(1975).
20. Hiddemann W, Clarkson BD, Buchner T, Melamed MR, Andreeff M, (1982) Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood 59: 216-225.
21. Pagano L, Fianchi L, Caira M, Rutella S, Leone G, (2007) The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 26: 3679-3690.
22. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID, (2005) Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105: 1295-1302.
23. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678-3684.